Latest News for: glucagon receptor

Edit

Weight-Loss Drug Use Has Risen Sharply Among Children and Adults with Type 1 Diabetes

Mega Doctor News 26 Mar 2025
“Trends in Obesity and Glucagon-like Peptide-1 Receptor Agonist Prescriptions in Type 1 Diabetes in the United States” was co-authored by Yunwen Xu, Justin Echouffo Tcheugui, Josef Coresh, Morgan ...
Edit

'Goal is to offer more innovative medicines'

The Times of India 26 Mar 2025
Tirzepatide is a first-in-class treatment that activates two hormone receptors - glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) -which play key roles in regulating blood sugar and appetite ... .
Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Pharmiweb 25 Mar 2025
(United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
Edit

Is Ozempic a game-changer for insulin resistance? What you need to know

WPXI 25 Mar 2025
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist ... Research indicates that GLP-1 receptor agonists like Ozempic may help regulate insulin levels, promote weight loss, and restore menstrual regularity in women with PCOS.
Edit

Diabetes Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 24 Mar 2025
KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd ... KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor.
Edit

A cure for 'resting bitch face': Plastic surgeons say rising numbers are affected by permanent ...

The Daily Mail 23 Mar 2025
The trend, they believe, may be triggered by so-called 'Ozempic face', an unintended by-product of weight loss jabs — collectively known as glucagon-like peptide-1 receptor agonists, or GLP-1s — typified by sunken eyes, gaunt cheeks and sagging skin.
Edit

Why is Mounjaro getting so much attention? Is it safer than Ozempic as a weight loss drug?

The Times of India 21 Mar 2025
Ozempic (semaglutide), from Novo Nordisk, is a GLP-1 (glucagon-like peptide-1) receptor agonist, and does not work at the GIP receptor like Mounjaro.However, both drugs are approved to lower blood ...
Edit

Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects

The Times of India 21 Mar 2025
... polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.119254020'The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India.
Edit

Weight-loss medicine goes on sale in India

Hindustan Times 21 Mar 2025
Weight-loss medicine goes on sale in India ... It activates what is known as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These receptors are expressed in key brain regions that regulate appetite ... ....
Edit

Eli Lilly brings in much-awaited weight-loss drug Mounjaro to India

Business Line 20 Mar 2025
BPCL to develop first hydrogen-fueled VTOL aircraft ecosystem ... The drug activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, it added ....
Edit

Ozempic-like weight loss drug Mounjaro launched in India - all you know to know

The Times of India 20 Mar 2025
... insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.Mounjaro is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve blood sugar control.
Edit

Mounjaro: Eli Lilly launches popular weight-loss drug in India

Hindustan Times 20 Mar 2025
According to the company statement, it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Edit

Popular diabetes drug, Mounjaro, launched in India

The Times of India 20 Mar 2025
... insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, offering a new approach to metabolic health management,' the manufacturing company Eli Lilly and Company has said.
Edit

Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, ...

GetNews 20 Mar 2025
Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression.
Edit

Students Concoct Ingenious Scheme To Grow Ozempic At Home

Futurism 19 Mar 2025
Though it could have lots of use cases in the future, Phytogene's first order of business is synthesizing glucagon-like peptide-1 (GLP-1) receptor agonists — the class of medications Novo Nordisk's ...
×